<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04671511</url>
  </required_header>
  <id_info>
    <org_study_id>MP-05-2021-2605</org_study_id>
    <nct_id>NCT04671511</nct_id>
  </id_info>
  <brief_title>Targeted Axillary Dissection (TAD) in Early-stage Node Positive Breast Cancer</brief_title>
  <acronym>TADEN</acronym>
  <official_title>Sentinel Node Biopsy and Targeted Axillary Dissection in Node-Positive Breast Cancer Patients With Clinically Negative Axilla</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jewish General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quebec Breast Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jewish General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: It is now standard for most breast cancer patients with 1-2 positive sentinel&#xD;
      nodes to avoid completion node dissection when eligibility criteria from the American College&#xD;
      of Surgeons Oncology Group (ACOSOG) Z0011 trial are met. The National Comprehensive Cancer&#xD;
      Network (NCCN) recently proposed to extend this indication to patients that present with&#xD;
      biopsy proven node positive disease if only 1 or 2 suspicious nodes are found on imaging,&#xD;
      these positive nodes are not palpable clinically, and the other eligibility criteria from the&#xD;
      Z0011 study are otherwise met. However, this recommendation is based on an expert consensus&#xD;
      and no study has yet confirmed the optimal method to stage the axilla in this patient&#xD;
      population.&#xD;
&#xD;
      PURPOSE: Evaluate the technical success rate and accuracy of sentinel node biopsy (SNB) and&#xD;
      the potential benefits of clipping and removing the biopsy proven node using radioactive seed&#xD;
      localisation (RSL) (SNB+RSL = Targeted Axillary Dissection (TAD)) in patients with biopsy&#xD;
      proven positive nodes, limited nodal disease in imaging and clinically negative axillary&#xD;
      examination.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective multicenter study. Patients with T1-2 Breast cancer and clinically&#xD;
      negative axilla on palpation, 1-2 suspicious nodes on ultrasound, and a biopsy proven&#xD;
      positive node (by core biopsy of fine needle aspiration) will have a radioactive seed (I125)&#xD;
      placed in their clipped node before surgery. At the time of surgery, patients that are&#xD;
      scheduled for breast conserving surgery or mastectomy will have sentinel node biopsy (SNB)&#xD;
      using radioactive dye (Tc99) +/- blue dye as well as retrieval of the clipped node using&#xD;
      radioactive seed localisation (RSL). Removal of the I125 radioactive seed in the clipped node&#xD;
      will be performed before the Tc99 counts are performed to prevent &quot;shine through&quot; and biased&#xD;
      measurements. Imaging of the surgical specimen will confirm retrieval of the clipped node.&#xD;
      Prospectively recorded information on pre-operative axillary imaging, characteristics of the&#xD;
      retrieved nodes in the operating room and detailed pathological analysis of each&#xD;
      corresponding node will be performed. Completion node dissection (CND) is not mandatory in&#xD;
      this study but recommended if the clipped positive node is not retrieved, if 4 nodes or more&#xD;
      are positive or if 3 nodes are positive in the absence of axillary radiation. The benefits of&#xD;
      adding RSL to SNB and the benefits of adding SNB to RSL staging of the axilla will be&#xD;
      evaluated in this study and will help to better define the value of using TAD in this patient&#xD;
      population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2021</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in recommended completion node dissection rate (CND) with the use of Targeted Axillary Dissection (TAD) vs. Sentinel Node Biopsy (SNB) alone.</measure>
    <time_frame>1 month</time_frame>
    <description>Recommended completion node dissection rate (CND) = false negative rate (FNR) + technical failure rate (TFR).&#xD;
TAD CND (TAD FNR + TAD TFR) vs. SNB CND (SNB FNR + SNB TFR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification rate of patients with three or more positive nodes using only radioactive seed localisation (RSL) vs. Targeted Axillary Dissection (TAD)</measure>
    <time_frame>1 month</time_frame>
    <description>Evaluate if the addition of SNB to RSL improves the ability to identify patients with 3+ positive nodes that do not otherwise meet the ACOSOG Z0011 criteria and require further regional axillary therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>False negative rate (FNR) of Targeted Axillary Dissection (TAD)</measure>
    <time_frame>1 month</time_frame>
    <description>Percentage of patients with successful removal of at least one node (using this method) where at least one positive node was not retrieved (using this method)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical failure rate (TFR) of Targeted Axillary Dissection (TAD)</measure>
    <time_frame>1 month</time_frame>
    <description>Percentage of patients with unsuccessful removal of at least one node using this method, including the clipped node</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>False negative rate (FNR) of Radioactive Seed Localisation (RSL)</measure>
    <time_frame>1 month</time_frame>
    <description>Percentage of patients with successful removal of at least one node (using this method) where at least one positive node was not retrieved (using this method)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical failure rate (TFR) of Radioactive Seed Localisation (RSL)</measure>
    <time_frame>1 month</time_frame>
    <description>Percentage of patients with unsuccessful removal of at least one node using this method, including the clipped node</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>False negative rate (FNR) of Sentinel Node Biopsy (SNB)</measure>
    <time_frame>1 month</time_frame>
    <description>Percentage of patients with successful removal of at least one node (using this method) where at least one positive node was not retrieved (using this method)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical failure rate (TFR) of Sentinel Node Biopsy (SNB)</measure>
    <time_frame>1 month</time_frame>
    <description>Percentage of patients with unsuccessful removal of at least one node using this method (clipped node or not)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">98</enrollment>
  <condition>Breast Cancer Female</condition>
  <condition>Early-stage Breast Cancer</condition>
  <condition>Lymph Node Metastases</condition>
  <condition>Axillary Metastases</condition>
  <condition>Sentinel Lymph Node</condition>
  <arm_group>
    <arm_group_label>Targeted Axillary Dissection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ultrasound of the axilla preoperative. Clipped biopsy proven positive node. I125 radioactive seed before surgery. Sentinel node biopsy using Tc99 +/- blue dye. Targeted Axillary Node Dissection performed at surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Targeted Axillary Dissection</intervention_name>
    <description>Sentinel Node Biopsy (SNB; using Tc99 +/- Blue dye) + Radioactive Seed Localisation (RSL) of clipped node using I125 seed = Targeted Axillary Dissection (TAD)</description>
    <arm_group_label>Targeted Axillary Dissection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Ultrasound of the axilla</intervention_name>
    <description>Prospectively recorded preoperative ultrasound of the axilla. Number of suspicious nodes recorded. Biopsy and clipping of the positive node.</description>
    <arm_group_label>Targeted Axillary Dissection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must be â‰¥ 18 years old.&#xD;
&#xD;
          -  Participants with a clinical T1 or T2 invasive ductal or lobular breast carcinoma,&#xD;
             regardless of estrogen/progesterone/human epidermal growth factor receptor 2 (HER2)&#xD;
             receptor status.&#xD;
&#xD;
          -  Participants with clinical (on palpation) N0 and up to two suspicious lymph nodes on&#xD;
             axillary ultrasound.&#xD;
&#xD;
          -  Participant with biopsy-proven positive axillary disease made by core needle biopsy or&#xD;
             fine-needle aspiration.&#xD;
&#xD;
          -  Participants must have an Eastern Cooperative Oncology Group (ECOG) Scale of&#xD;
             Performance Status less than 2.&#xD;
&#xD;
          -  Participants must understand, accept, and have signed the approved consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant with previous ipsilateral axillary surgery, including sentinel lymph node&#xD;
             biopsy.&#xD;
&#xD;
          -  Participants with distant metastases.&#xD;
&#xD;
          -  Participants that have had previous radiotherapy to the axillary nodes.&#xD;
&#xD;
          -  Participants who received neoadjuvant therapy.&#xD;
&#xD;
          -  If the injection of blue dye is planned, patients with hypersensitivity or allergy to&#xD;
             isosulfan blue, patent blue, methylene blue or radiocolloid dye.&#xD;
&#xD;
          -  Participants who are unable to provide informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-FranÃ§ois Boileau, MD,MSc,FRCSC</last_name>
    <role>Study Chair</role>
    <affiliation>Jewish General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>LÃ©amarie Meloche-Dumas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre hospitalier de l'UniversitÃ© de MontrÃ©al (CHUM)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Erica Patocskai, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centre hospitalier de l'UniversitÃ© de MontrÃ©al (CHUM)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-FranÃ§ois Boileau, MD,MSc,FRCSC</last_name>
    <phone>514-340-8222</phone>
    <phone_ext>24210</phone_ext>
    <email>jean-francois.boileau@mcgill.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>LÃ©amarie Meloche-Dumas, MD</last_name>
    <phone>438-826-7489</phone>
    <email>leamarie.meloche-dumas@umontreal.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre hospitalier de l'UniversitÃ© de MontrÃ©al</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 3E4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LÃ©amarie Meloche-Dumas, MD</last_name>
      <phone>438-826-7489</phone>
      <email>leamarie.meloche-dumas@umontreal.ca</email>
    </contact>
    <contact_backup>
      <last_name>Erica Patocskai, MD</last_name>
      <phone>514 890-8000</phone>
      <phone_ext>26607</phone_ext>
      <email>erica.patocskai.med@ssss.gouv.qc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>LÃ©amarie Meloche-Dumas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erica Patocskai, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle Trop, MPH,FRCPC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Danh Tran-Thanh, MD,MSc,FRCPC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mona El Khoury, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-FranÃ§ois Boileau, MD,MSc,FRCSC</last_name>
      <phone>514-340-8222</phone>
      <phone_ext>24210</phone_ext>
      <email>jean-francois.boileau@mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Stephanie Wong, MD,MPH,FRCSC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesca Marie Grazia Proulx, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Livia Florianova, MD,MSc,FRCPC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-FranÃ§ois Boileau, MD,MSc,FRCSC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019 Jan;69(1):7-34. doi: 10.3322/caac.21551. Epub 2019 Jan 8.</citation>
    <PMID>30620402</PMID>
  </reference>
  <reference>
    <citation>Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, Saha S, Hunt KK, Morrow M, Ballman K. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010 Sep;252(3):426-32; discussion 432-3. doi: 10.1097/SLA.0b013e3181f08f32.</citation>
    <PMID>20739842</PMID>
  </reference>
  <reference>
    <citation>Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, Yiangou C, Horgan K, Bundred N, Monypenny I, England D, Sibbering M, Abdullah TI, Barr L, Chetty U, Sinnett DH, Fleissig A, Clarke D, Ell PJ. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006 May 3;98(9):599-609. Erratum in: J Natl Cancer Inst. 2006 Jun 21;98(12):876.</citation>
    <PMID>16670385</PMID>
  </reference>
  <reference>
    <citation>Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, Ashikaga T, Weaver DL, Mamounas EP, Jalovec LM, Frazier TG, Noyes RD, Robidoux A, Scarth HM, Wolmark N. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010 Oct;11(10):927-33. doi: 10.1016/S1470-2045(10)70207-2.</citation>
    <PMID>20863759</PMID>
  </reference>
  <reference>
    <citation>Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, Ollila DW, Hansen NM, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Morrow M. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA. 2017 Sep 12;318(10):918-926. doi: 10.1001/jama.2017.11470.</citation>
    <PMID>28898379</PMID>
  </reference>
  <reference>
    <citation>National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Breast Cancer, Version 1.2020. 2020.</citation>
  </reference>
  <reference>
    <citation>Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, Lebeau A, Liedtke C, von Minckwitz G, Nekljudova V, Schmatloch S, Schrenk P, Staebler A, Untch M. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013 Jun;14(7):609-18. doi: 10.1016/S1470-2045(13)70166-9. Epub 2013 May 15.</citation>
    <PMID>23683750</PMID>
  </reference>
  <reference>
    <citation>Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Leitch AM, Kuerer HM, Bowling M, Flippo-Morton TS, Byrd DR, Ollila DW, Julian TB, McLaughlin SA, McCall L, Symmans WF, Le-Petross HT, Haffty BG, Buchholz TA, Nelson H, Hunt KK; Alliance for Clinical Trials in Oncology. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013 Oct 9;310(14):1455-61. doi: 10.1001/jama.2013.278932.</citation>
    <PMID>24101169</PMID>
  </reference>
  <reference>
    <citation>Boileau JF, Poirier B, Basik M, Holloway CM, Gaboury L, Sideris L, Meterissian S, Arnaout A, Brackstone M, McCready DR, Karp SE, Trop I, Lisbona A, Wright FC, Younan RJ, Provencher L, Patocskai E, Omeroglu A, Robidoux A. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015 Jan 20;33(3):258-64. doi: 10.1200/JCO.2014.55.7827. Epub 2014 Dec 1.</citation>
    <PMID>25452445</PMID>
  </reference>
  <reference>
    <citation>Classe JM, Loaec C, Gimbergues P, Alran S, de Lara CT, Dupre PF, Rouzier R, Faure C, Paillocher N, Chauvet MP, Houvenaeghel G, Gutowski M, De Blay P, Verhaeghe JL, Barranger E, Lefebvre C, Ngo C, Ferron G, Palpacuer C, Campion L. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study. Breast Cancer Res Treat. 2019 Jan;173(2):343-352. doi: 10.1007/s10549-018-5004-7. Epub 2018 Oct 20.</citation>
    <PMID>30343457</PMID>
  </reference>
  <reference>
    <citation>Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, Bedrosian I, Hobbs BP, DeSnyder SM, Hwang RF, Adrada BE, Shaitelman SF, Chavez-MacGregor M, Smith BD, Candelaria RP, Babiera GV, Dogan BE, Santiago L, Hunt KK, Kuerer HM. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. J Clin Oncol. 2016 Apr 1;34(10):1072-8. doi: 10.1200/JCO.2015.64.0094. Epub 2016 Jan 25.</citation>
    <PMID>26811528</PMID>
  </reference>
  <reference>
    <citation>Caudle AS, Yang WT, Mittendorf EA, Black DM, Hwang R, Hobbs B, Hunt KK, Krishnamurthy S, Kuerer HM. Selective surgical localization of axillary lymph nodes containing metastases in patients with breast cancer: a prospective feasibility trial. JAMA Surg. 2015 Feb;150(2):137-43. doi: 10.1001/jamasurg.2014.1086.</citation>
    <PMID>25517573</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 7, 2020</study_first_submitted>
  <study_first_submitted_qc>December 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>May 19, 2021</last_update_submitted>
  <last_update_submitted_qc>May 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jewish General Hospital</investigator_affiliation>
    <investigator_full_name>Jean-Francois Boileau</investigator_full_name>
    <investigator_title>MD, MSc, FRCSC, Surgical Oncologist, Associate Professor Surgery and Oncology, McGill University, Director JGH Breast Clinical Trials Group</investigator_title>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>targeted axillary dissection</keyword>
  <keyword>sentinel lymph node biopsy</keyword>
  <keyword>clinically negative axilla</keyword>
  <keyword>metastatic axillary lymph nodes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Lymphatic Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

